Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab With or Without Cabozantinib in Advanced Nasopharyngeal Carcinoma
NCT05904080Phase 2Suspended
- Sponsor
- National Cancer Institute
- Start
- Feb 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in nasopharyngeal carcinoma (NPC), sponsored by National Cancer Institute. Started Feb 2024; status: suspended.
02
Drugs
cabozantinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05904080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904080.